Research interests
- Central serotonin system and its contribution to mammal consciousness, affect, and cognition
- Serotonergic hallucinogens and correlates of hallucinogenic activity (e.g., haemo-and pyramidal-cellular 5-HT2Aergics)
- Serotonergic thermoregulation (e.g., 5-HT2A in hyperthermia)
- Neuropsychopharmacology of substances of abuse (and mechanisms of addiction)
Current project
Central Institute of Mental Health Mannheim, Institute of Psychopharmacology (supported by Seed Funding for Research at ZI):
- Psilocybin in animal models of addiction
- Substrates of psychedelic Wet Dog Shake
- Research on the thalamocortical filter hypothesis of psychedelic drug action (incl. LSD, psilocybin, and quipazine)
Methodological focus: Chemo- and optogenetic Neurophysiology
(incl. multisite, multimodal in vivo fibre photometry)
Former projects
- Imperial College London (supported by MSCA and The Beckley Foundation): The project addressed the 5-HT2Aergics of (brain-imminent) neck-arterial blood-flow as a function of thermoregulation (for further information: growkudos.com), as well as the haemo- and pyramidal-cellular corticodynamics of the "psychedelic signature move" (for further information: MSCA blog)
- Otto-von-Guericke University, Magdeburg (supported by LOM [Performance-based allocation of funds, Univ. Magdeburg]): Regulation of serotonin (5-HT) 2A receptors and its relevance for tolerance to serotonergic hallucinogens (incl., LSD, DMT, and DOB) (see: youtube.com 1 and youtube.com 2)
- Otto-von-Guericke University, Magdeburg: Evaluation of the antidepressant-like properties of LSD in an animal model of depression (i.e., olfactory bulbectomy) (see: psypost.org and youtube.com 2)
______________________________________________
Publications
Song C, Chang T, Buchborn T, Knöpfel T (2025). Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition. Biorxiv, doi.org/10.1101/2025.03.10.642385.
Heller N, Barrett F, Buchborn T, Collerton D, Dupuis D, Halberstadt A, Jardri R, Noorani T, Preller K, Taylor JP, Waters F, Winston B, and Leptourgos P (2025). Visual Hallucinations in Serotonergic Psychedelics and Lewy Body diseases. PsyArXiv, doi.org/10.31234/osf.io/7x8q4_v2.
Buchborn T, Kettner H, Kaertner L, Meinhardt M (2023). The ego in psychedelic drug action – ego defenses, ego boundaries, and the therapeutic role of regression. Front. Neurosci., 17. doi.org/10.3389/fnins.2023.1232459 (open access).
Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T (2023). Cortical Correlates of Psychedelic-Induced Shaking BehaviorRevealed by Voltage Imaging. Int. J. Mol. Sci., 24, 9463. doi.org/10.3390/ijms24119463 (open access).
Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL (2023). Body mass index (BMI) does not predict responses to psilocybin. J. Psychopharmacol., 37, 1, 107-116. doi.org/10.1177/02698811221131994 (open access).
Kärtner L, Steinborn M, Kettner H, Spriggs M, Roseman L, Buchborn T, Balaet M, Timmermann C, Erritzoe D, Carhart-Harris R (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci. rep., 11, 1941. doi.org/10.1038/s41598-021-81446-7 (open access).
Buchborn T (2020). Verhaltens- und molekularbiologische Untersuchungen zur Grundlage der Toleranz gegenüber serotonergen Halluzinogenen. Dissertation. Otto-von-Guericke Univ., Magdeburg. dx.doi.org/10.25673/35375 (open access).
Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T (2020). The 5-HT2AR agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner. J. Psychopharmacol., 34, 7, 786–794. doi: 10.1177/0269881120903465 (green open access).
Buchborn T, Lyons T, Knöpfel T (2018). Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice. Front. pharmacol., 9, 17. doi: 10.3389/fphar.2018.00017 (open access).
Buchborn T, Grecksch G, Dieterich DC, Höllt V (2016). Tolerance to lysergic acid diethylamide (LSD): Overview, correlates, and clinical implications. In: Preedy VR (ed.), Neuropathology of Drug Addictions and Substance Misuse, Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects, 846-858. Academic Press. doi:10.1016/B978-0-12-800212-4.00079-0 (green open access).
Buchborn T, Schröder H, Koch T, Kahl E, Dieterich DC, Grecksch G, Höllt V (2016). Differential tolerance to lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT) – A matter of serotonin (5-HT) 2A receptor downregulation? Naunyn-Schmiedeberg's Arch. Pharmacol., 389, Suppl. 1, S63.
Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V (2015). Tolerance to LSD and DOB induced Shaking behaviour: Differential adaptations of frontocortical 5-HT2A and glutamate receptor binding sites. Behav. Brain Res., 281, 62–68. doi:10.1016/j.bbr.2014.12.014 (green open access).
Buchborn T, Schröder H, Höllt V, Grecksch G (2014). Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J. Psychopharmacol., 28, 6, 545-552. doi: 10.1177/0269881114531666 (green open access).
Buchborn T, Kahl E, Höllt V, Koch T (2012). Agonist-selective internalization of the human 5-HT2A receptor. Naunyn-Schmiedeberg´s Arch. Pharmacol., 385, Suppl. 1, S17. doi: 10.1007/s00210-012-0736-0 (green open access).
Buchborn T, Schröder H, Dieterich DC, Koch T, Börner C, Becker A, Grecksch G, Höllt V (in preparation). Tolerance to serotonergic hallucinogens - Differential regulation of 5-HT2A receptors by LSD and DMT.
Heller N, Barrett F, Buchborn T, Collerton D, Dupuis D, Halberstadt A, Jardri R, Noorani T, Preller K, Taylor JP, Waters F, Winston B, and Leptourgos P (2025). Visual Hallucinations in Serotonergic Psychedelics and Lewy Body diseases. PsyArXiv, doi.org/10.31234/osf.io/7x8q4_v2.
Buchborn T, Kettner H, Kaertner L, Meinhardt M (2023). The ego in psychedelic drug action – ego defenses, ego boundaries, and the therapeutic role of regression. Front. Neurosci., 17. doi.org/10.3389/fnins.2023.1232459 (open access).
Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T (2023). Cortical Correlates of Psychedelic-Induced Shaking BehaviorRevealed by Voltage Imaging. Int. J. Mol. Sci., 24, 9463. doi.org/10.3390/ijms24119463 (open access).
Spriggs MJ, Giribaldi B, Lyons T, Rosas FE, Kärtner LS, Buchborn T, Douglass HM, Roseman L, Timmermann C, Erritzoe D, Nutt DJ, Carhart-Harris RL (2023). Body mass index (BMI) does not predict responses to psilocybin. J. Psychopharmacol., 37, 1, 107-116. doi.org/10.1177/02698811221131994 (open access).
Kärtner L, Steinborn M, Kettner H, Spriggs M, Roseman L, Buchborn T, Balaet M, Timmermann C, Erritzoe D, Carhart-Harris R (2021). Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci. rep., 11, 1941. doi.org/10.1038/s41598-021-81446-7 (open access).
Buchborn T (2020). Verhaltens- und molekularbiologische Untersuchungen zur Grundlage der Toleranz gegenüber serotonergen Halluzinogenen. Dissertation. Otto-von-Guericke Univ., Magdeburg. dx.doi.org/10.25673/35375 (open access).
Buchborn T, Lyons T, Song C, Feilding A, Knöpfel T (2020). The 5-HT2AR agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner. J. Psychopharmacol., 34, 7, 786–794. doi: 10.1177/0269881120903465 (green open access).
Buchborn T, Lyons T, Knöpfel T (2018). Tolerance and Tachyphylaxis to Head Twitches Induced by the 5-HT2A Agonist 25CN-NBOH in Mice. Front. pharmacol., 9, 17. doi: 10.3389/fphar.2018.00017 (open access).
Buchborn T, Grecksch G, Dieterich DC, Höllt V (2016). Tolerance to lysergic acid diethylamide (LSD): Overview, correlates, and clinical implications. In: Preedy VR (ed.), Neuropathology of Drug Addictions and Substance Misuse, Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects, 846-858. Academic Press. doi:10.1016/B978-0-12-800212-4.00079-0 (green open access).
Buchborn T, Schröder H, Koch T, Kahl E, Dieterich DC, Grecksch G, Höllt V (2016). Differential tolerance to lysergic acid diethylamide (LSD) and dimethyltryptamine (DMT) – A matter of serotonin (5-HT) 2A receptor downregulation? Naunyn-Schmiedeberg's Arch. Pharmacol., 389, Suppl. 1, S63.
Buchborn T, Schröder H, Dieterich DC, Grecksch G, Höllt V (2015). Tolerance to LSD and DOB induced Shaking behaviour: Differential adaptations of frontocortical 5-HT2A and glutamate receptor binding sites. Behav. Brain Res., 281, 62–68. doi:10.1016/j.bbr.2014.12.014 (green open access).
Buchborn T, Schröder H, Höllt V, Grecksch G (2014). Repeated lysergic acid diethylamide in an animal model of depression: Normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J. Psychopharmacol., 28, 6, 545-552. doi: 10.1177/0269881114531666 (green open access).
Buchborn T, Kahl E, Höllt V, Koch T (2012). Agonist-selective internalization of the human 5-HT2A receptor. Naunyn-Schmiedeberg´s Arch. Pharmacol., 385, Suppl. 1, S17. doi: 10.1007/s00210-012-0736-0 (green open access).
Buchborn T, Schröder H, Dieterich DC, Koch T, Börner C, Becker A, Grecksch G, Höllt V (in preparation). Tolerance to serotonergic hallucinogens - Differential regulation of 5-HT2A receptors by LSD and DMT.